PRESS RELEASE: FDA clearance for honey-based wound care

The FDA approved the honey based L-Mesitran® Hydro, Border, Net and L-Mesitran® Active wound care products for the USA market. Triticum is very proud of this achievement. The 510(k) clearance opens up new opportunities for the honey-based wound care. Honey has unique qualities in the support of wound healing. Clinical studies show that honey is capable of cleaning wounds fast and support the wound healing process. "In Europe we have been involved in wound care since 2002 and we are the market leaders with our revolutionary and innovative products," says mr. Joost Postmes (CEO of Triticum), "we are the market leaders and we have come a long way with the FDA clearance. It is a recognition by the world's leading authority in this field of the quality and efficacy of our products." The Triticum products are estimated to be available in Q1 of 2008 on the USA market. More information on

Suggested Articles

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.

A new study shows how circular ecDNA outside of the chromosome in cancer cells drives oncogenes, making tumors more aggressive.

The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.